Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tilactase
- Development stage
- Unknown
- Lead developer
- Rameda Pharmaceutical Company
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
Ramelact is an oral food supplement containing tilactase (lactase enzyme, specifically Tolerase L, 6000 ALU), developed and marketed by Rameda. It is designed to support the digestion of lactose in individuals with lactose intolerance. By hydrolyzing lactose into glucose and galactose in the acidic environment of the stomach, Ramelact helps prevent common gastrointestinal symptoms associated with dairy consumption, such as bloating, gas, abdominal cramps, and diarrhea.
- Brand names
- Ramelact
- Other names
- acid lactasebeta-D-galactosidasebeta-galactosidaselactase
Beyond the preview
Go deeper on tilactase.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tilactase.